Compare Church & Dwight Co., Inc. (CHD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Church & Dwight Co., Inc. trades at $101.59 (market cap $24.38B), while Zimmer Biomet Holdings Inc trades at $95.52 (market cap $18.55B). The key difference: Church & Dwight Co., Inc. is the larger of the two by market cap, and Church & Dwight Co., Inc. pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| CHD | ZBH | |
|---|---|---|
Market Cap | $24.38B | $18.55B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $107.71 |
52-Week Low | $81.60 | $79.58 |
Enterprise Value | $26.38B | $25.61B |
Dividend Yield | 1.2% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $103.30, up 0.06% today, near its consensus price target of $103.57. The stock shows bullish technical signals with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, Q2 2026 earnings met estimates with 5.8% organic sales growth, and the company raised full-year guidance. Recent news highlights volume-driven performance and market share gains.
The outlook remains positive given raised earnings guidance and consistent dividend payments, but risks include high valuation multiples and competitive pressures. Analyst consensus is bullish with 53% buy ratings, supporting a stable investment case for long-term growth in the consumer staples sector.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
